相关实验视频

Updated: Jun 4, 2025

Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow

Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow

Published on: January 8, 2014

使用Fc融合技术延长IgG降解酶 (IdeS) 的半衰期

Victoria Daventure¹, Melissa Bou-Jaoudeh¹, Emna Hannachi¹

¹Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, CNRS, Sorbonne Université, Université Paris Cité, Paris, France.

European journal of immunology

|December 20, 2024

概括

与Fc片段融合的工程化伊米利菲达酶 (IdeS) 显示出延长半衰期和持续的IgG降低活性. 这一创新可以改善IgG介导疾病的治疗方法,需要长时间的治疗效果.

科学领域:

生物化学生化学
免疫学免疫学免疫学
蛋白质工程是指蛋白质工程.

背景情况:

乳酶 (IdeS) 是一种细菌蛋白酶,可以分裂人类的IgG,从而减少其半衰期和Fc介导功能.
IdeS用于预防移植排斥,并对IgG介导的自身免疫性疾病进行评估.
由于Ides的半衰期很短,因此在需要重复剂量的慢性疾病中使用Ides是有限的.

研究的目的:

在体内设计IdeS-Fc融合蛋白来延长IdeS的IgG减弱作用.
评估二价 (IdeS-Fcdiv) 和单价 (IdeS-Fcmonov) 的IdeS-Fc融合蛋白的疗效和药物动力学特性.

主要方法:

开发IdeS-Fc融合蛋白 (双价和单价异构体).
通过IdeS-Fc融合蛋白评估IgG水解动力学.
在体内半衰期的确定和IdeS-Fcmonov与IdeS.相比的残留IgG裂变的评估.

主要成果:

两种IdeS-Fc融合蛋白都有效地将人类IgG分裂成F(ab') 2和Fc片段,尽管动力学比原生IdeS慢.
与IdeS.Fcmonov相比,IdeS-Fcmonov的半衰期延长了七倍,与IdeS.Fcmonov相比,半衰期延长了七倍.
在注射后的时间点,IdeS-Fcmonov在注射后的时间点显示出明显更好的残留IgG裂变.

结论:

IdeS-Fc融合蛋白代表了一个可行的策略,可以延长Ides的体内治疗持续时间.
IdeS-Fcmonov为持续的IgG水解提供了一种有希望的方法,可能有利于慢性IgG介导疾病.
开发的IdeS-Fc融合蛋白为增强的IgG消耗疗法提供了概念证明,具有快速临床转化潜力.

关键词:

想法的想法消灭IgG,消除IgG.伊米利菲达酶是一种药物动力学药物动力学

更多相关视频

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension

High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension

Published on: December 28, 2015

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tagging and Fusion Proteins

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...